Please login to the form below

Not currently logged in
Email:
Password:

Santhera CEO Klaus Schollmeier joins SuppreMol

He has experience at ING BHF-Bank, BASF, Knoll and Abbott

Santhera CEO Klaus Schollmeier joins SuppreMolFormer CEO of Santhera Pharmaceuticals Klaus Schollmeier has joined Germany-based biopharma SuppreMol as CEO.

Dr Schollmeier (pictured right) had served as CEO of Santhera since its formation in 2004, and was appointed chairman in October 2011.

He has both senior scientific and business experience, previously serving as managing director healthcare-biotechnology at ING BHF-Bank; head of oncology-immunology research at BASF; and general manager for BASF's operations in Western Europe.

Prior to his time at BASF, he held senior roles at Knoll and Abbott.

In his new position at autoimmune disease specialists SuppreMol, Schollmeier succeeds Professor Peter Buckell who retires.

Dr Thomas Hecht, chairman of the company's advisory board, paid tribute to Prof Buckell for his “long-standing commitment” as he welcomed Dr Schollmeier.

He said: "The company has a very promising product candidate for the treatment of autoimmune diseases in phase II clinical development with important clinical and regulatory milestones ahead. Dr Schollmeier will bring the necessary experience to the company to advance SuppreMol's products towards a Biologics License Application.”

This product is SM101, which is being investigated for its use in the treatment of primary immune thrombocytopenia (ITP) and systemic lupus erythematosus (SLE).

5th April 2013

From: Research, Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

The concordance conundrum: understanding the complexities of behaviour change
Understanding behaviour change looks at the six fundamental steps required to change human behaviour and discusses why HCPs need to start here if concordance is to be improved....
The concordance conundrum: creating space for open dialogue
Growing numbers of patients want a partnership model with their HCP, whereby both parties are equally involved in the decision-making process. This model has been linked with an increase in...
Switzerland
Switzerland: a life sciences hub
Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...

Infographics